Phase 3 Thyroid Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are willing to take part voluntarily, sign a consent form, and are able to follow the study requirements.
• People who have been confirmed through a tissue or cell sample to have locally advanced or metastatic differentiated thyroid cancer.
• People aged 18 to 74 years old (based on the date the consent form is signed).
• People whose general physical ability to carry out daily activities is rated at a good level (a standard medical score of 0 or 1 on a scale used by doctors to measure this).
• People whose life expectancy is estimated to be more than 12 weeks.
• People who have at least one measurable area of cancer, as confirmed using standard imaging measurement guidelines (RECIST 1.1).
• People whose cancer has continued to grow after receiving up to 2 rounds (and no more than 3 types) of a specific class of targeted cancer medications that affect blood vessel growth (VEGFR TKI therapies).
• People whose cancer has been confirmed as no longer responding to radioactive iodine treatment, based on one or more specific medical findings (confirm with trial site for full details).
• People whose thyroid-stimulating hormone (TSH) level is at or below 0.5 mIU/L while on TSH-suppressing medication.
• People whose blood test results meet specific thresholds for red blood cells, white blood cells, platelets, liver function, kidney function, clotting ability, and protein levels (confirm with trial site for the exact values required).
• People of childbearing potential who agree to use effective contraception during the study and for 6 months afterward; women must have a negative pregnancy test within 7 days before joining, and men must also agree to use contraception during and for 6 months after the study.

Who may not be able to join:

• People who have a type of thyroid cancer called undifferentiated (anaplastic) thyroid carcinoma or medullary thyroid carcinoma.
• People who have had or currently have another type of cancer, unless it was treated with surgery alone and there has been no return of cancer for 5 or more years, or unless it was a cured cervical carcinoma in situ, a non-melanoma skin cancer, or a superficial bladder tumour of a specific early stage.
• People who have conditions that make it difficult to take oral (swallowed) medications, such as trouble swallowing, ongoing diarrhoea, or a bowel blockage.
• People who still have significant side effects from previous cancer treatments that have not improved to a mild level, with some specific exceptions allowed (confirm with trial site for details).
• People who have a known allergy to any of the inactive ingredients in the study drug.
• People who have taken part in another clinical trial involving anti-cancer drugs within the 4 weeks before joining this study.
• People who, in the treating doctor's judgment, have other circumstances that could seriously affect their safety or their ability to complete the study.

Important: Always verify eligibility with the trial site directly before applying.